Sun Pharma Q1 Preview: R&D spends to hit margins; profits may rise 10%

Brokerages expect a satisfactory quarter for Sun Pharma giant with a steady growth in the topline as well as bottomline on a year-on-year (YoY) basis, however, sequentially the bottomline may get hit